Literature DB >> 31019956

Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report.

Laura Bender1, Guillaume Meyer2, Elisabeth Quoix3, Bertrand Mennecier3.   

Abstract

Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.

Entities:  

Keywords:  Anaplastic lymphoma kinase rearrangement (ALK rearrangement); ceritinib; diffuse interstitial pneumonitis; non-small cell lung cancer (NSCLC)

Year:  2019        PMID： 31019956      PMCID： PMC6462648          DOI： 10.21037/atm.2019.01.24

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


  3 in total

1.  Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.

Authors:  Ken Koshikawa; Jiro Terada; Mitsuhiro Abe; Shunichiro Iwasawa; Masashi Sakayori; Keiichiro Yoshioka; Yasutaka Hirasawa; Hajime Kasai; Yohei Kawasaki; Kenji Tsushima; Koichiro Tatsumi
Journal:  Thorac Cancer       Date:  2020-04-01       Impact factor: 3.500

Review 2.  Repurposing of Kinase Inhibitors for Treatment of COVID-19.

Authors:  Ellen Weisberg; Alexander Parent; Priscilla L Yang; Martin Sattler; Qingsong Liu; Qingwang Liu; Jinhua Wang; Chengcheng Meng; Sara J Buhrlage; Nathanael Gray; James D Griffin
Journal:  Pharm Res       Date:  2020-08-10       Impact factor: 4.580

3.  Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion.

Authors:  Meng Qiao; Chao Zhao; Qian Liu; Yan Wang; Jingyun Shi; Terry L Ng; Fei Zhou; Xuefei Li; Tao Jiang; Shuo Yang; Guanghui Gao; Anwen Xiong; Jiayu Li; Wei Li; Fengying Wu; Xiaoxia Chen; Chunxia Su; Shengxiang Ren; Caicun Zhou; Jun Zhang
Journal:  Transl Lung Cancer Res       Date:  2020-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.